BCLI Stock News & Analysis | Latest Updates

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...

August 14, 2025Earnings

BCLI News

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

BrainStorm Secures Strategic U.S. Manufacturing Deal With Minaris For Phase 3b ALS Trial Production

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Market-Moving News for May 19th

BrainStorm Receives FDA Clearance To Initiate Its Phase 3b Trial Of NurOwn For Treatment Of ALS

Brainstorm Cell Q1 EPS $(0.45) Beats $(0.97) Estimate

BrainStorm To Present Pharmacogenomic Data On NurOwn At ISCT 2025, Highlighting UNC13A Genotype In Amyotrophic Lateral Sclerosis

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BrainStorm Cell Therapeutics Submits IND Amendment to FDA for Phase 3b Trial of NurOwn in Amyotrophic Lateral Sclerosis

12 Health Care Stocks Moving In Friday's After-Market Session

Brainstorm Cell FY 2024 GAAP EPS $(2.31) Beats $(2.56) Estimate

A Preview Of Brainstorm Cell's Earnings

BrainStorm Cell Therapeutics Has Been Granted The Exact Compliance Extension It Requested From The Nasdaq Hearings Panel Through June 30, 2025, To Regain Compliance With Certain Continued Listing Standards Of The Nasdaq Capital Market

Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn